Pembrolizumab KEYNOTE-010

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

Not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects

Less serious adverse events observed

Other adjustments

Pembrolizumab KEYNOTE-010

SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

S

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: EMA: Pembrolizumab is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab. (2 mg/kg and 10mg/kg pooled data). FDA: Pembrolizumab for the treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] greater than or equal to 50%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
Experimental Arm: Pembrolizumab
Control Arm: Docetaxel